Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis

G. Izquierdo, P. O'Connor, X. Montalban, P. Von Rosenstiel, M. Cremer, A. De Vera, N. Sfikas, G. Francis, E. W. Radue, Ludwig Kappos*

*Autor corresponent d’aquest treball

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

18 Cites (Scopus)

Resum

We present here results at 60 months (M), from the extension component of a phase 2, randomized, placebo-controlled, double-blind, six-month study evaluating oral fingolimod (1.25 mg or 5 mg daily) in relapsing multiple sclerosis. Placebo patients from the core study were re-randomized to fingolimod 1.25 mg or 5 mg in the extension. All patients received 1.25 mg fingolimod after the M24 visit. A total of 140/281 (49.8%) patients completed M60. Fingolimod treatment was associated with a low annualized relapse rate (0.2 relapses/ year), low MRI activity, and a modest rate of disability progression in those treated for five years. No new safety issues were reported.
Idioma originalEnglish
Pàgines (de-a)877-881
Nombre de pàgines5
RevistaMultiple Sclerosis Journal
Volum20
Número7
DOIs
Estat de la publicacióPublicada - de juny 2014

Fingerprint

Navegar pels temes de recerca de 'Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis'. Junts formen un fingerprint únic.

Com citar-ho